Infectious Disease
Show
- Nanotechnology
- Nanosilver No ‘Silver Bullet’
- A popular treatment for microbial infections may lose its effectiveness when used in long-term
- 568 0
- Genetic Research
- For some peptides, killing bacteria is an inside job
- Rice chemists’ analysis advances research on alternatives to antibiotics
- 3238 0
- Industry News
- Potential for False Positive Results with Abbott Molecular Inc. Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits
- The FDA has issued an alert on September 17, 2021, regarding the potential for false-positive COVID-19 testing results using certain kits...
- 2805 0
- Infectious Disease
- FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19
- The FDA has revised the EUA to authorize bamlanivimab and etesevimab monoclonal antibody therapy for certain individuals in/with specific conditions
- 2393 0
-
- Nanotechnology
- Nanosilver No ‘Silver Bullet’
- A popular treatment for microbial infections may lose its effectiveness when used in long-term
- 568 0
-
- Genetic Research
- For some peptides, killing bacteria is an inside job
- Rice chemists’ analysis advances research on alternatives to antibiotics
- 3238 0
-
- Industry News
- Potential for False Positive Results with Abbott Molecular Inc. Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits
- The FDA has issued an alert on September 17, 2021, regarding the potential for false-positive COVID-19 testing results using certain kits...
- 2805 0
-
- Infectious Disease
- FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19
- The FDA has revised the EUA to authorize bamlanivimab and etesevimab monoclonal antibody therapy for certain individuals in/with specific conditions
- 2393 0
Load More
